Leading the pack of biotechs vying for a piece of the generalized myasthenia gravis (gMG) market with an FcRn inhibitor, argenx on Tuesday unveiled keenly anticipated positive late-stage data on its lead asset, bringing it one step closer to regulatory approval.
Despite steroids, immunosuppressants, acetylcholinesterase inhibitors, and Alexion’s Soliris, patients with the rare, chronic neuromuscular disorder (more than 100,000 in the United States and Europe) don’t necessarily benefit from these existing options, leaving room for the crop of FcRn inhibitors in development.
"triple" - Google News
May 26, 2020 at 05:56PM
https://ift.tt/2zwifJe
UPDATED: Merck makes a triple play on Covid-19: buying out a vaccine biotech, partnering on another program and adding an antiviral to the mix - Endpoints News
"triple" - Google News
https://ift.tt/3dc0blF
https://ift.tt/2WoIFUS
Bagikan Berita Ini
0 Response to "UPDATED: Merck makes a triple play on Covid-19: buying out a vaccine biotech, partnering on another program and adding an antiviral to the mix - Endpoints News"
Post a Comment